NEW YORK (GenomeWeb) – Becton Dickinson today reported that its second quarter revenues increased around 4 percent year over year driven by growth in its BD Medical and BD Biosciences business segments.

BD reported total revenues of $2.07 billion for the three months ended March 31, up from $2.00 billion for the second quarter of 2013. It fell short of the average analyst estimate of $2.09 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.